Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Intercell on Acquisition of Antibody Technology Platform


LONDON, 6 May, 2010 — Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos’ platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases. Covington & Burling LLP advised Intercell on the transaction.

Intercell is a Vienna Stock Exchange listed biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Cytos is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products − the Immunodrugs™.

The London-based Covington corporate team was led by partners Peter Laveran and Lucinda Osborne, with of counsel Morag Peberdy, associate Robin Blaney and trainee-solicitor Sarah Cowlishaw.

Share this article: